7,976 Shares in Revvity Inc. (NYSE:RVTY) Bought by Arcus Capital Partners LLC

Arcus Capital Partners LLC bought a new position in shares of Revvity Inc. (NYSE:RVTY - Free Report) during the first quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor bought 7,976 shares of the company's stock, valued at approximately $844,000.

A number of other institutional investors also recently modified their holdings of the company. Assetmark Inc. lifted its stake in Revvity by 3,700.0% during the 4th quarter. Assetmark Inc. now owns 266 shares of the company's stock valued at $30,000 after acquiring an additional 259 shares in the last quarter. Optiver Holding B.V. bought a new position in shares of Revvity during the fourth quarter valued at about $33,000. Quarry LP boosted its holdings in Revvity by 45.7% during the fourth quarter. Quarry LP now owns 303 shares of the company's stock worth $34,000 after purchasing an additional 95 shares during the last quarter. Millstone Evans Group LLC bought a new stake in Revvity in the 4th quarter worth about $38,000. Finally, Vermillion Wealth Management Inc. purchased a new stake in Revvity in the 4th quarter valued at about $41,000. 86.65% of the stock is owned by institutional investors and hedge funds.

Revvity Stock Performance

RVTY traded down $0.94 on Friday, hitting $101.47. The company's stock had a trading volume of 253,696 shares, compared to its average volume of 1,119,228. The company's 50 day simple moving average is $94.56 and its 200-day simple moving average is $104.61. The company has a quick ratio of 2.99, a current ratio of 3.58 and a debt-to-equity ratio of 0.41. Revvity Inc. has a 12 month low of $87.70 and a 12 month high of $129.50. The firm has a market cap of $11.96 billion, a P/E ratio of 43.18, a price-to-earnings-growth ratio of 2.53 and a beta of 0.98.

Revvity (NYSE:RVTY - Get Free Report) last posted its quarterly earnings results on Monday, April 28th. The company reported $1.01 EPS for the quarter, topping analysts' consensus estimates of $0.96 by $0.05. Revvity had a return on equity of 7.73% and a net margin of 10.35%. The firm had revenue of $664.76 million during the quarter, compared to analyst estimates of $662.30 million. During the same period last year, the company earned $0.98 earnings per share. The business's revenue for the quarter was up 2.3% on a year-over-year basis. Analysts forecast that Revvity Inc. will post 4.94 EPS for the current year.

Revvity Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Friday, August 8th. Investors of record on Friday, July 18th will be paid a dividend of $0.07 per share. The ex-dividend date is Friday, July 18th. This represents a $0.28 annualized dividend and a yield of 0.28%. Revvity's dividend payout ratio is currently 11.91%.

Wall Street Analysts Forecast Growth

A number of equities analysts have recently weighed in on the company. The Goldman Sachs Group cut their target price on Revvity from $140.00 to $125.00 and set a "buy" rating on the stock in a research note on Tuesday, April 29th. Wall Street Zen raised Revvity from a "hold" rating to a "buy" rating in a research report on Saturday, June 28th. Raymond James Financial restated an "outperform" rating and issued a $120.00 price objective (down previously from $145.00) on shares of Revvity in a research note on Tuesday, April 29th. UBS Group upgraded Revvity from a "neutral" rating to a "buy" rating and lowered their target price for the stock from $145.00 to $115.00 in a research note on Thursday, May 1st. Finally, JPMorgan Chase & Co. reduced their price target on shares of Revvity from $120.00 to $100.00 and set a "neutral" rating for the company in a research report on Tuesday, April 29th. Four equities research analysts have rated the stock with a hold rating and twelve have issued a buy rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and an average price target of $123.07.

Revvity Profile

Revvity, Inc provides health sciences solutions, technologies, and services in the Americas, Europe, and Asia, and internationally. The Life Sciences segment provides instruments, reagents, informatics, software, subscriptions, detection, imaging technologies, warranties, training, and services. Its Diagnostics segment provides instruments, reagents, assay platforms, and software products for the early detection of genetic disorders, such as pregnancy and early childhood, as well as infectious disease testing in the diagnostics market.